Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularLMAT +0.20%99 3-Year EPS without NRI Growth Rate is 26.20% as of Jun. 2026, which is 128% above its 10-year median of 11.50. GuruFocus rates LMAT with a GF Score™ of 99/100 and a GF Value™ of $95.52 (Modestly Undervalued). Among 662 Medical Devices & Instruments companies, LeMaitre Vascular ranks better than 73.26% on this metric.
During the past 12 months, LeMaitre Vascular's average EPS without NRI Growth Rate was 32.80% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 26.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 14.60% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 14.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of LeMaitre Vascular was 49.70% per year. The lowest was -51.10% per year. And the median was 11.50% per year.
LeMaitre Vascular (NAS:LMAT) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
LeMaitre Vascular 3-Year EPS without NRI Growth Rate Related Terms
LMAT vs BLFS, KMTS, XRAY: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's 3-Year EPS without NRI Growth Rate falls into.
LeMaitre Vascular 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 26.20% mean?
LeMaitre Vascular (LMAT) has a 3-Year EPS without NRI Growth Rate of 26.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for LeMaitre Vascular and its competitors. This is 128% above median its historical median of 11.50. According to the industry distribution chart, LeMaitre Vascular ranks #177 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 26.7%.
Is LeMaitre Vascular's 3-Year EPS without NRI Growth Rate too high?
LeMaitre Vascular's current 3-Year EPS without NRI Growth Rate of 26.20% is 128% above median its 10-year median of 11.50. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 7.90. LeMaitre Vascular's value of 26.20% is 231.6% above this industry median. Based on the distribution chart, LeMaitre Vascular ranks #177 out of 662 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, LeMaitre Vascular has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's 3-Year EPS without NRI Growth Rate compare to BLFS and KMTS?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #177 out of 662 companies for 3-Year EPS without NRI Growth Rate. This puts LeMaitre Vascular in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 7.90. LeMaitre Vascular's value of 26.20% is 231.6% above this benchmark. While the company's 10-year median is 11.50 vs. the industry median of 7.90, LeMaitre Vascular has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 7.90, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current 3-Year EPS without NRI Growth Rate of 26.20% is 231.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for LeMaitre Vascular and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current 3-Year EPS without NRI Growth Rate is 26.20%, which is 128% above median its own 10-year median of 11.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.52, compared to a current price of $80.68 — trading 15.5% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 26.20%, which is 128% above median its 10-year median of 11.50 and 231.6% above the Medical Devices & Instruments industry median of 7.90. LeMaitre Vascular's overall GF Score™ is 99/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current 3-Year EPS without NRI Growth Rate is 26.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $80.68 is trading 15.5% below its estimated GF Value™ of $95.52.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
3-Year EPS without NRI Growth Rate: 26.20% (128% above median its 10-year median of 11.50)
GF Value™: $95.52 vs. price of $80.68 (15.5% below fair value)
Industry Position: 231.6% above the Medical Devices & Instruments median (#177 of 662)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
99GF Score
Get the complete analysis for LMAT
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
